×
About 16,350 results

ALLMedicine™ Amyotrophic Lateral Sclerosis Center

Research & Reviews  6,013 results

Pridopidine modifies disease phenotype in a SOD1 mouse model of Amyotrophic Lateral Scl...
https://doi.org/10.1111/ejn.15608
The European Journal of Neuroscience; Estévez-Silva HM, Mediavilla T et. al.

Jan 27th, 2022 - Amyotrophic lateral sclerosis (ALS) is a lethal and incurable neurodegenerative disease due to the loss of upper and lower motor neurons, which leads to muscle weakness, atrophy, and paralysis. Sigma-1 receptor (σ-1R) is a ligand-operated protein ...

Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophi...
https://doi.org/10.1093/brain/awab285
Brain : a Journal of Neurology; Riva N, Gentile F et. al.

Jan 26th, 2022 - Phosphorylated TDP-43 (pTDP-43) aggregates in the cytoplasm of motor neurons and neuroglia in the brain are one of the pathological hallmarks of amyotrophic lateral sclerosis. Although the axons exceed the total volume of motor neuron soma by seve...

The amyloid state of proteins: A boon or bane?
https://doi.org/10.1016/j.ijbiomac.2022.01.115
International Journal of Biological Macromolecules; Hassan MN, Nabi F et. al.

Jan 26th, 2022 - Proteins and their aggregation is significant field of research due to their association with various conformational maladies including well-known neurodegenerative diseases like Alzheimer's (AD), Parkinson's (PD), and Huntington's (HD) diseases. ...

Functional loss and mortality in randomized clinical trials for amyotrophic lateral scl...
https://doi.org/10.1002/cpt.2533
Clinical Pharmacology and Therapeutics; van Eijk RPA, Roes KCB et. al.

Jan 26th, 2022 - Amyotrophic lateral sclerosis (ALS) is a rapidly progressive disease leading to death in, on average, three to five years after first symptom onset. Consequently, there is frequently a non-negligible number of patients who die during the course of...

see more →

Guidelines  3 results

Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyot...
https://doi.org/10.1002/mus.26408
Muscle & Nerve; Pattee GL, Plowman EK et. al.

Jan 9th, 2019 - Universally established comprehensive clinical bulbar scales objectively assessing disease progression in amyotrophic lateral sclerosis (ALS) are currently lacking. The goal of this working group project is to design a best practice set of provisi...

ESPEN guideline clinical nutrition in neurology.
https://doi.org/10.1016/j.clnu.2017.09.003
Clinical Nutrition (Edinburgh, Scotland); Burgos R, Bretón I et. al.

Dec 25th, 2017 - Neurological diseases are frequently associated with swallowing disorders and malnutrition. Moreover, patients with neurological diseases are at increased risk of micronutrient deficiency and dehydration. On the other hand, nutritional factors may...

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2764728
Neurology Miller RG, Jackson CE et. al.

Oct 14th, 2009 - To systematically review evidence bearing on the management of patients with amyotrophic lateral sclerosis (ALS). The authors analyzed studies from 1998 to 2007 to update the 1999 practice parameter. Topics covered in this section include breaking...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  179 results

Online Self-Compassion Course for pALS (Compassion pALS)
https://clinicaltrials.gov/ct2/show/NCT05202743

Jan 21st, 2022 - Optimizing quality of life for people with ALS is a primary goal of ALS multidisciplinary care, Therefore, it is especially important to conduct research into interventions to address the psychological needs and well-being of people with ALS. Rece...

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
https://clinicaltrials.gov/ct2/show/NCT04944784

Jan 13th, 2022 - COURAGE-ALS is a Phase 3, double-blind, randomized, placebo-controlled trial of reldesemtiv in patients aged 18 to 80 with ALS. The screening and qualification period for the trial will be no more than 14 days in duration. Approximately 555 eligib...

Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
https://clinicaltrials.gov/ct2/show/NCT05189106

Jan 12th, 2022 - Overview of Clinical Trial: Many age-associated neurodegenerative diseases, including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS), are associated with increased inflammatory signaling in the central nervous system. While there...

Use of 1 Minute Sit to Stand Test for Physical Capacity and Effort Related Desaturation in Amyotrophic Lateral Sclerosis
https://clinicaltrials.gov/ct2/show/NCT05151211

Jan 11th, 2022 - The aim of this study is to investigate the usability of the 1 Minute Sit to Stand Test (1 MSTS) in evaluating physical capacity and effort-related desaturation in individuals with Amyotrophic Lateral Sclerosis (ALS). In this context, patients dia...

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intrathecal Injection for ALS
https://clinicaltrials.gov/ct2/show/NCT05003921

Jan 5th, 2022 - Amyotrophic lateral sclerosis is a devastating disease. There is evidence that mesenchymal stem cell treatment is safe and can improve the prognosis of afflicted patients. Patients with ALS will receive three intrathecal injections of cultured all...

see more →

News  319 results

Long-Term Adjunctive Edaravone for ALS: Latest Findings
https://www.medscape.com/viewarticle/966717

Jan 17th, 2022 - Dr Simon Witzel Long-term add-on treatment with intravenous (IV) edaravone is not associated with any change in the progression of amyotrophic lateral sclerosis (ALS), new research shows. These findings contradict those from the drug trial the US ...

Long NFL Careers Significantly Boost ALS Risk, but What's at Play?
https://www.medscape.com/viewarticle/964853

Dec 15th, 2021 - National Football League players are nearly four times more likely to develop amyotrophic lateral sclerosis (ALS) than men in the general population, with long-term players at greatest risk, a new study shows. The findings are the latest to show i...

Lipid Levels Tied to ALS Risk
https://www.medscape.com/viewarticle/958730

Sep 14th, 2021 - Elevated levels of high-density lipoprotein (HDL) and apolipoprotein A1 (apoA1) are associated with a reduced risk for amyotrophic lateral sclerosis (ALS), new research shows. The study also linked a higher ratio of total cholesterol to HDL with a...

Eyes Spy Brain Amyloid; Irisin-Cognition Link; A Look at Anti-IgLON5 Disease
https://www.medpagetoday.com/neurology/generalneurology/94184

Aug 24th, 2021 - Retinal fundus imaging to detect amyloid deposits in eyes correlated with brain amyloid PET, a small pilot study showed. (Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring) Mentally stimulating jobs may lower dementia risk, three ...

AstraZeneca's Antibody Therapy Prevents COVID-19, Study Shows
https://www.medscape.com/viewarticle/956953

Aug 23rd, 2021 - (Reuters) - AstraZeneca's new antibody therapy reduced the risk of people developing COVID-19 symptoms by 77% in a late-stage trial, putting the drugmaker on track to offer protection to those who respond poorly to vaccines. The company said on Fr...

see more →

Patient Education  9 results see all →